Skip to main content
ArticleOPEN ACCESS

Hepatitis C in the rituximab era

Blood
DOI: 10.1182/blood-2010-09-307827
12Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In a multicenter Japanese study, Ennishi et al have demonstrated both the benefits and the risks of adding rituximab to CHOP chemotherapy (R-CHOP) in patients with diffuse large B-cell lymphoma (DLBCL) and hepatitis C virus (HCV) infection.

Cite

CITATION STYLE

APA

Foran, J. M. (2010, December 9). Hepatitis C in the rituximab era. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2010-09-307827

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free